LONDON, February 12, 2013 /PRNewswire/ --
Any drug company's stock price hinges on the performance of its drugs. One of the very first steps involved in marketing a drug is getting the approval of FDA. Dynavax Technologies Corporation (NASDAQ: DVAX) is one such company that pointed out that the point recently. The stock plummeted when its drug candidate received poor reviews. However, the same Hepatitis B drug is now waiting for the final approval and the FDA's decision will have a major impact on the future direction taken by Dynavax Technologies stock. Similarly, GlaxoSmithKline Plc (NYSE: GSK) is also awaiting FDA's decision for its major drug candidates. The drug industry is also dealing with problems like patent expiries and falling revenues as GlaxoSmithKline posted weak results. The drug industry is expected to see consolidation this year as major companies may acquire smaller biotech firms to plug the losses caused by expired patents. StockCall analysts initiated preliminary technical research on Dynavax and GlaxoSmithKline. These free reports are accessible by signing today at http://www.stockcall.com/register
GlaxoSmithKline Posts Q4 Results
GlaxoSmithKline Plc reported lower income for its fourth quarter of the year. The company earned 57 cents per share, down from 90 cents per share it had earned a year earlier. Its revenue for the quarter stood at $11 billion. Overall, the results were lower-than-expected. However, all is not bad when it comes to GlaxoSmithKline. The company sports healthy margins. It is also doing well on the growth front as it finalized the acquisition of Human Genome Sciences. With this acquisition, the company also gained the access to Benlysta, which is used to treat Lupus. Register now to download the free research on GlaxoSmithKline at http://www.StockCall.com/GSK021213.pdf
GlaxoSmithKline stock increased 1.72 percent in the past 12 months and the company is taking steps to improve its stock price performance. It is looking to expand its footprints in emerging markets. The company recently inked a new joint venture in India for developing a multi-use vaccine for ailments such as Hepatitis B. GlaxoSmithKline also has strong pipeline as it expects to get reviews for six of its drugs in 2013. These drugs may prove to be a major catalyst for GlaxoSmithKline stock, as and when they receive approval. Improvement in global and European economy is also likely to have positive impact on the stock. Apart from growth prospects, the stock also offers mouthwatering dividend yield of 5.10 percent.
Dynavax Technologies Waits for FDA Decision
Dynavax Technologies Corporation is waiting for FDA's decision for its Hepatitis B drug Heplisav. The decision is due out on February 24th. If approved, the drug may open up a lucrative market for Dynavax Technologies. However, there are certain apprehensions about the drug receiving unconditional approval. The free technical analysis on Dynavax Technologies is available by signing up at http://www.StockCall.com/DVAX021213.pdf
Dynavax Technologies was thoroughly beaten down late last year, after getting negative safety vote for Heplisav. However, since then the stock has recovered nicely. It is currently trading slightly above its 20-day moving average price of $3.26, showing neutral trend. However, it is expected to breakout, if its Hepatitis B drug receives the approval. There are quite high chances of the drug receiving approval and the stock looks attractive at the moment.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com